NASDAQ:KMDA - Kamada Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Kamada Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $5.83 +0.07 (+1.22 %) (As of 03/31/2020 04:00 PM ET) Add Compare Today's Range$5.75Now: $5.83▼$6.1450-Day Range$4.56MA: $5.71▼$7.1352-Week Range$4.40Now: $5.83▼$8.00Volume117,136 shsAverage Volume87,109 shsMarket Capitalization$259.55 millionP/E Ratio10.80Dividend YieldN/ABeta1.32 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Kamada Ltd. develops, produces, and markets plasma-derived protein therapeutics for orphan indications. It operates through two segments, Proprietary Products and Distribution. The company offers respiratory products, including Glassia for use in augmentation and maintenance therapy in adults with emphysema due to congenital Alpha-1 Antitrypsin (AAT) deficiency. It also provides KamRAB for prophylaxis of rabies disease; KamRho (D) IM to treat prophylaxis of hemolytic disease of newborns; KamRho (D) IV for immune thermobocytopunic purpura; and snake bite antiserum to treat snake bites by the vipera palaestinae and echis coloratus, as well as human transferrin that is used as a cultural medium for diagnostic assays and cell cultures. In addition, Kamada Ltd. provides Heparin sodium injection to treat thrombo-embolic disorders; Albumin and Albumin 4% for maintenance of blood plasma; and coagulation factors comprising Factor VIII and Factor IX, as well as IXIARO vaccine. Its products in pipeline are G1-AAT (IV) for graft versus host disease and L1-AAT (1V) for lung transparent, which are in Phase II stage; and D1-AAT (IV) for type-1 diabetes, Inhaled AAT for AAT deficiency, and AAT (liquid) for lung preservation and recombinant AAT, which are in early stage development. Further, the company distributes respiratory products, including Bramitob to manage chronic pulmonary infection and FOSTER for the treatment of asthma; and immunoglobulins comprising IVIG 5% for the treatment of various immunodeficiency-related conditions; Varitect, a varicella zoster immunoglobulin; Zutectra and Hepatect CP for prevention of hepatitis B virus; and Megalotect, a CMV immunoglobulin. It markets its products through strategic partners in the United States, as well as through distributors internationally. Kamada Ltd. has strategic partnerships with Takeda Pharmaceutical Company Limited; PARI GmbH; and Kedrion S.p.A. Kamada Ltd. was founded in 1990 and is headquartered in Rehovot, Israel.Read More Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:KMDA Previous Symbol CUSIPN/A CIK1567529 Webhttp://www.kamada.com/ Phone972-8940-6472Debt Debt-to-Equity RatioN/A Current Ratio4.39 Quick Ratio3.07Price-To-Earnings Trailing P/E Ratio10.80 Forward P/E Ratio22.42 P/E GrowthN/A Sales & Book Value Annual Sales$127.19 million Price / Sales2.04 Cash Flow$0.64 per share Price / Cash Flow9.13 Book Value$3.04 per share Price / Book1.92Profitability EPS (Most Recent Fiscal Year)$0.55 Net Income$22.25 million Net Margins17.50% Return on Equity17.56% Return on Assets14.09%Miscellaneous Employees408 Outstanding Shares44,520,000Market Cap$259.55 million Next Earnings Date5/12/2020 (Estimated) OptionableNot Optionable Receive KMDA News and Ratings via Email Sign-up to receive the latest news and ratings for KMDA and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:KMDA Rates by TradingView Kamada (NASDAQ:KMDA) Frequently Asked Questions How has Kamada's stock been impacted by COVID-19 (Coronavirus)? Kamada's stock was trading at $5.15 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, KMDA shares have increased by 13.2% and is now trading at $5.83. View which stocks have been mosted impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Kamada? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kamada in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Kamada. When is Kamada's next earnings date? Kamada is scheduled to release its next quarterly earnings announcement on Tuesday, May 12th 2020. View our earnings forecast for Kamada. How were Kamada's earnings last quarter? Kamada Ltd. (NASDAQ:KMDA) released its earnings results on Wednesday, February, 12th. The biotechnology company reported $0.13 earnings per share for the quarter, hitting analysts' consensus estimates of $0.13. The biotechnology company had revenue of $32.07 million for the quarter, compared to the consensus estimate of $31.63 million. Kamada had a return on equity of 17.56% and a net margin of 17.50%. View Kamada's earnings history. What guidance has Kamada issued on next quarter's earnings? Kamada updated its FY 2020 Pre-Market earnings guidance on Wednesday, February, 12th. The company provided EPS guidance of for the period. The company issued revenue guidance of $132-137 million, compared to the consensus revenue estimate of $135.67 million. What price target have analysts set for KMDA? 2 brokerages have issued 1 year price objectives for Kamada's stock. Their forecasts range from $7.00 to $11.00. On average, they anticipate Kamada's share price to reach $9.00 in the next twelve months. This suggests a possible upside of 54.4% from the stock's current price. View analysts' price targets for Kamada. What are Wall Street analysts saying about Kamada stock? Here are some recent quotes from research analysts about Kamada stock: 1. According to Zacks Investment Research, "Kamada Ltd. is a biopharmaceutical company. It develops, produces and markets therapeutics based on chromatographic purification technology. The company offers bio-therapeutics for specialty proteins, specific immunoglobulins and other prescription medicines. Kamada Ltd. is headquartered in Ness Ziona, Israel. " (2/18/2020) 2. HC Wainwright analysts commented, "Our price target of $11/share is based on an equally weighted composite of: (a) $14.26/share, as a 35x multiple of taxed and diluted FY23 GAAP EPS of $0.84 discounted back to and (b) an NPV of $8.1/share (discount rate 12%, growth rate 2%). Risks to our investment thesis and target price include: (1) failure of AAT (IV and IH) to achieve peak commercial revenue estimates in our model (due to market size, penetration rates, and/ or pricing); (2) failure of IH-AAT in clinical studies; (3) failure of IH-AAT to secure regulatory approval; and (4) other potential pipeline failures." (8/7/2019) Has Kamada been receiving favorable news coverage? News coverage about KMDA stock has been trending positive this week, according to InfoTrie. The research group scores the sentiment of press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Kamada earned a news impact score of 3.0 on InfoTrie's scale. They also assigned news articles about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the near future. View the latest news aboutKamada. Are investors shorting Kamada? Kamada saw a increase in short interest during the month of March. As of March 13th, there was short interest totaling 30,000 shares, an increase of 581.8% from the February 27th total of 4,400 shares. Based on an average daily trading volume, of 127,400 shares, the short-interest ratio is currently 0.2 days. Currently, 0.1% of the shares of the company are short sold. View Kamada's Current Options Chain. Who are some of Kamada's key competitors? Some companies that are related to Kamada include Esperion Therapeutics (ESPR), Opko Health (OPK), Enanta Pharmaceuticals (ENTA), Aimmune Therapeutics (AIMT), Akebia Therapeutics (AKBA), Supernus Pharmaceuticals (SUPN), Intra-Cellular Therapies (ITCI), Revance Therapeutics (RVNC), Endo International (ENDP), Kiniksa Pharmaceuticals (KNSA), Y-mAbs Therapeutics (YMAB), Odonate Therapeutics (ODT), Phibro Animal Health (PAHC), Rocket Pharmaceuticals (RCKT) and CannTrust (CNTTF). What other stocks do shareholders of Kamada own? Based on aggregate information from My MarketBeat watchlists, some companies that other Kamada investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), NIC (EGOV), Allergan (AGN), Aegean Marine Petroleum Network (ANW), Zoetis (ZTS) and Micron Technology (MU). Who are Kamada's key executives? Kamada's management team includes the following people: Mr. Amir London, Chief Exec. Officer (Age 50)Mr. Chaime Orlev, Chief Financial Officer (Age 49)Mr. Eran Nir, VP of Operations & Plant Mang. (Age 46)Mr. David Tsur, Co-Founder & Active Deputy Chairman (Age 68)Dr. Naveh Tov M.D., Ph.D., VP of Clinical Devel. & Medical Director for Pulmonary Diseases (Age 55) What is Kamada's stock symbol? Kamada trades on the NASDAQ under the ticker symbol "KMDA." How do I buy shares of Kamada? Shares of KMDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Kamada's stock price today? One share of KMDA stock can currently be purchased for approximately $5.83. How big of a company is Kamada? Kamada has a market capitalization of $259.55 million and generates $127.19 million in revenue each year. The biotechnology company earns $22.25 million in net income (profit) each year or $0.55 on an earnings per share basis. Kamada employs 408 workers across the globe. View additional information about Kamada. What is Kamada's official website? The official website for Kamada is http://www.kamada.com/. How can I contact Kamada? Kamada's mailing address is 2 HOLTZMAN ST. SCIENCE PARK, REHOVOT L3, 7670402. The biotechnology company can be reached via phone at 972-8940-6472 or via email at [email protected] MarketBeat Community Rating for Kamada (NASDAQ KMDA)Community Ranking: 2.2 out of 5 ( )Outperform Votes: 224 (Vote Outperform)Underperform Votes: 276 (Vote Underperform)Total Votes: 500MarketBeat's community ratings are surveys of what our community members think about Kamada and other stocks. Vote "Outperform" if you believe KMDA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KMDA will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 3/31/2020 by MarketBeat.com StaffFeatured Article: Hold Rating
